- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07776405
A Double-Blinded Study on Rapid and Sustained Pain Relief Topical Cannabidiol for Plantar Fasciitis
Topical Cannabidiol for Plantar Fasciitis: A Double-Blinded Study on Rapid and Sustained Pain Relief
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Plantar fasciitis is one of the most common causes of plantar heel pain, affecting millions of adults annually and accounting for a large proportion of musculoskeletal complaints seen in orthopaedic and sports medicine clinics. The condition is typically caused by repetitive microtrauma and inflammation at the plantar fascia's insertion on the calcaneus, leading to chronic pain, functional impairment, and limitations in daily activities. Despite its prevalence, effective and well-tolerated long-term treatments remain limited. Current management strategies, including stretching, orthotics, corticosteroid injections, and physical therapy, often provide only temporary relief or are associated with adverse effects from repeated use.
Cannabidiol (CBD), a non-psychoactive phytocannabinoid derived from hemp, has gained attention for its potential anti-inflammatory and analgesic properties. Preclinical and clinical studies have demonstrated CBD's ability to modulate inflammatory markers, reduce cytokine activity, and improve pain perception in various musculoskeletal and neuropathic conditions. These mechanisms make it a promising candidate for targeting inflammation-driven pain disorders such as plantar fasciitis. Although CBD has been studied for arthritis, tendon injuries, and generalized pain syndromes, no published trials have yet evaluated its efficacy in plantar fasciitis specifically.
A recent scoping review on topical CBD interventions confirmed this absence of evidence, highlighting a significant gap in the current literature regarding CBD's role in localized foot and heel pain. This lack of research underscores an unmet clinical need to assess whether transdermal delivery of CBD could provide measurable short- and long-term benefits in patients with plantar fasciitis.
This study aims to address that gap by evaluating a 6000 mg transdermal CBD cream (Tolcylen®, Marlinz Pharma) for both immediate and sustained pain reduction in adults with plantar fasciitis. By using a randomized, double-blinded, placebo-controlled design, we intend to determine whether topical CBD can offer a safe, non-invasive, and effective alternative or adjunct to current treatments. The results of this investigation may contribute to the emerging evidence on topical cannabinoids in orthopaedic pain management and inform future clinical practice guidelines.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Shea Herlihy, MS
- Telefonnummer: 352-273-7361
- E-mail: herliso@ortho.ufl.edu
Undersøgelse Kontakt Backup
- Navn: Antony Merendino, DPM
- Telefonnummer: 352-273-7044
- E-mail: merena@ortho.ufl.edu
Studiesteder
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32611
- University of Florida Department of Orthopaedics
-
Kontakt:
- Shea Herlihy, MS
- Telefonnummer: 352-273-7361
- E-mail: herliso@ortho.ufl.edu
-
Kontakt:
- Antony Merendino, DPM
- Telefonnummer: 352-273-7044
- E-mail: merena@ortho.ufl.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Patients aged 18-85
- Clinical diagnosis of plantar fasciitis by a qualified provider
- Symptomatic for at least four weeks with plantar heel pain consistent with plantar fascia involvement
- Baseline average pain score that meets eligibility threshold as defined in the protocol (?)
- Willing to apply assigned cream once daily and attend needed visits (?)
Exclusion Criteria:
- Special populations and consent limitations. Pregnancy, breastfeeding, prisoners, inability to provide informed consent, or inability to complete study procedures
- Contraindications to topical products or CBD. History of allergy or sensitivity to cannabinoids, excipients, or topical creams used in the study
- Confounding dermatologic conditions at the application site. Open wounds, active infection, dermatitis, ulceration, or recent burns on the heel or midfoot
- Recent or planned procedures that alter outcomes. Corticosteroid injection, platelet rich plasma, surgery, immobilization, or shockwave therapy within the protocol washout window
- Concurrent therapies that confound pain outcomes. Routine use of systemic opioids, regular use of nonsteroidal anti-inflammatory drugs beyond rescue parameters, new analgesic starts during the study, or use of other topical analgesics on the study area
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Participants who receive a transdermal cannabidiol cream
Dosing is three pumps per application which delivers approximately one point five milliliters of cream.
Application is once daily to the most tender plantar fascia region for the entire study month
|
The active product is the study CBD cream supplied by the manufacturer.
Dosing is three pumps per application which delivers approximately one point five milliliters of cream.
Application is once daily to the most tender plantar fascia region for the entire study month.
The first dose will be taught and supervised in clinic using a glove.
The cream will be massaged into the affected area for at least forty-five seconds.
Skin must be clean and dry before application.
No other topical agents may be placed on the study area during the study period.
|
|
Placebo komparator: Participants who receive a matched placebo
Dosing is three pumps per application which delivers approximately one point five milliliters of cream.
Application is once daily to the most tender plantar fascia region for the entire study month
|
The control group will receive a placebo cream identical in appearance, texture, scent, and packaging to the active product but containing no cannabidiol.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
• Immediate pain relief, measured by change in numeric rating scale (0-10) from baseline to ten minutes after supervised application.
Tidsramme: Daily for one month
|
Daily for one month
|
|
|
• One-month changes in average daily pain score compared to baseline.
Tidsramme: Daily for one month
|
Daily for one month
|
|
|
• Global patient satisfaction
Tidsramme: Daily for one month.
|
measured using a five-point Likert scale assessing overall perceived improvement.
|
Daily for one month.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Duration of immediate pain relief following initial application
Tidsramme: Daily for one month
|
Daily for one month
|
|
|
Adherence to protocol measured by patient logs and pump counts
Tidsramme: Daily for one month
|
Daily for one month
|
|
|
Incidence of adverse effects
Tidsramme: Daily for one month
|
Occurrence of negative side effects
|
Daily for one month
|
|
Rescue analgesic use
Tidsramme: Daily for one month
|
Daily for one month
|
|
|
Time to perceived improvement in symptoms
Tidsramme: Daily for one month
|
Daily for one month
|
|
|
6. PROMIS Pain Interference questionnaire
Tidsramme: At enrollment and at end of once month
|
At enrollment and at end of once month
|
|
|
7. Foot Function Index questionnaires
Tidsramme: At enrollment and at one month
|
At enrollment and at one month
|
|
|
8. Return to normal activity - the number of days required for participants to resume full standing or walking tolerance without pain
Tidsramme: Once during one month
|
Once during one month
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IRB#: 202501843
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .